View Author
-12 il -12 patient cancer injection study level effect response tumor administration interleukin cytokine treatment trastuzumab concentration rhuil ifn-y therapy 0.5 activation production plasma phase result adjuvant complex chapter blood h ¡d group group vaccination -12. interleukin 12 rhuil -12 antigen t cells phase i study h ϩd group factor 1.0 model baseline receptor induction coagulation -10 breast docetaxel toxicity rhull human immunol fibrinolysi cell cancer il -12 administration anti-tumor interleukin -12 value tnf-a side effects table month il -10 nk cells range neutrophils anti-tumor effects il -6 il -12 injection il -12. combination lymphocytes portielje cell carcinoma tn f-a progression immunity il -8 ll -12
2 Most Recent Publications
|
Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: Hertax trial
(Article)
Hamberg, P. Bos, M.M.E.M. Pruijt, J.F.M. Loosveld, O.J.L. Smit, W.M. Muller, E.W. Schmitz, P.I.M. Seynaeve, C.M. Klijn, J.G.M. Braun, H.J.J. Stouthard, J.M.L. Deijk, G.A. van Erdkamp, F.L.G. Stelt-Frissen, I.N. van der Bontenbal, M. Creemers, G.J.M. Portielje, J.E.A. |
2011-04-01
|
|
Clinical and biological effects of interleukin 12 in patients with renal cell carcinoma
(Doctoral Thesis)
Portielje, J.E.A. |
2002-11-06
|
